Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dostarlimab + Niraparib vs Niraparib vs Chemotherapy in Endometrial or Ovarian Carcinosarcoma
NCT03651206Phase 3Recruiting
- Sponsor
- ARCAGY
- Start
- Jul 2020
- Primary completion
- Jun 2027
- Modality
- Small Molecules, Immune Checkpoint Inhibitors
- Countries
- 3
01
Overview
Phase 3, randomised, open-label trial of dostarlimab and niraparib in ovarian carcinosarcoma (OCS) and endometrial carcinosarcoma (3 arms), sponsored by ARCAGY. Primary endpoints: Response Rate at 4 months and Overall Survival at 1 year. Started Jul 2020; status: recruiting.
02
Drugs
dostarlimabniraparib
03
Conditions
ovarian carcinosarcoma (OCS)endometrial carcinosarcoma
Beyond the preview
Go deeper on NCT03651206.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03651206.